Cardima Inc. (fka CADMQ)

[Renee]

CADMQ revoked:

http://www.sec.gov/litigation/admin/2013/34-70077.pdf

[sidedraft]

Suspension ended. Trading on the greys started today:

http://www.dtcc.com/downloads/legal/imp_notices/2013/nscc/otc/OTC-108.pdf

[Renee]

CADMQ SEC Suspension:

http://www.sec.gov/litigation/suspensions/2013/34-69617.pdf

Order:

http://www.sec.gov/litigation/suspensions/2013/34-69617-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2013/34-69618.pdf

[DDhawk]

""Q''...that was fast & furious...now: CADMQ

http://www.otcbb.com/asp/dailylist_detail.asp?d=12/22/2010&mkt_ctg=ALL
Sure was some bizarre (very suspicous) trades since the 8/10/10 lifetime of this Dog.
No use hanging around here anymore...bye & gl
Final pps: .25cents

[DDhawk]

Dbl. Market Cap on 100 shrs(=$75.) at that...LOL

[HDOGTX]

CADM 8k out +97%

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, DC 20549


FORM 8-K


CURRENT REPORT


Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest reported): September 14, 2010


CARDIMA, INC.

(Exact name of registrant as specified in charter)

Delaware 000-22419 94-3177883
(State or Other Jurisdiction of (Commission File Number) (IRS Employer
Incorporation or Organization) Identification No.)


47266 Benicia Street, Fremont, California, 94538
(Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: [phone]


Copies to:


Richard A. Friedman, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32 nd Floor
New York, New York 10006
Phone: [phone]
Fax: [phone]


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







--------------------------------------------------------------------------------



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.




On September 14, 2010, Dr. Richard Gaston and Mr. Sung Chun resigned as directors of Cardima, Inc. (the “Company”). There were no disagreements between Dr. Gaston and Mr. Chun and the Company that led to their resignation.












--------------------------------------------------------------------------------






SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARDIMA, INC.

Date: September 16, 2010 By: /s/ Robert Cheney
Name: Robert Cheney
Chief Executive Officer

[DDhawk]

Now down to .30cents...amazing !
Would have been a sweet ride to the top but...
the fall looks fatal...my condolences.

Glad I didn't jump-in...
saw no reason for the POP in the 1st place.

[DDhawk]

Down $4.90 to 2.10 on 2,300 shares...a wild stock here.
* and still no news ????

[DDhawk]

3. X 3. and zero trades...WTH ?

[DDhawk]

TZ1 to $7 friggin' dollars in 3 days...OMG !!!

[DDhawk]

UP 2 1/2M %....OMG...got to be a fatfinger aberration.
Either that or...there are a bunch of [newly] rich folks here now...
congrats if that's the case.

[di4]

Cardima Surgical Ablation System Featured in Podium Presentation by Dr. Li Poa at ACTS 2009 Meeting
Company to Exhibit Surgical Ablation System Products at ACTS 2009 and American Association of Thoracic Surgeons Meetings
May 6, 2009 4:00:00 AM
Copyright Business Wire 2009


Email Story Discuss on ZenoBank

View Additional ProfilesFREMONT, Calif.--(BUSINESS WIRE)-- Cardima, Inc. (OTCBB: CADM) today announced that surgical ablation thought leader, Dr. Li Poa, will present data from his experience with the Cardima Surgical Ablation System at the ACTS 2009: Advanced Cardiac Techniques in Surgery Meeting on May 7, 2009. Cardima also will showcase its products and technologies at the ACTS 2009 meeting being held on May 6-7, 2009 in New York, as well as at the 89th Annual Meeting of the American Association for Thoracic Surgery (AATS) May 9-13, 2009 in Boston. Cardima executives will attend both conferences to meet with industry executives and interested investors.

Dr. Poa, FACS, Chief of Cardiothoracic Surgery and Cardiac Surgery Program Director at Stamford Hospital, Connecticut, and faculty member of Columbia University, New York, heads the Cardima Center of Excellence and Training Program at Stamford Hospital. "I look forward to presenting data collected from procedures using the Cardima Surgical Ablation System in my presentation, 'Keys to Surgical Ablation: Stamford Experience with the Cardima System,'" Dr. Poa said. "The Cardima system is capable of creating a fairly complete, complex lesion set during both open- and closed-chest procedures. It can reliably and reproducibly establish both entrance and exit conduction block, which is an important attribute for achieving effective, long-term ablation results. Additionally, the system is capable of creating continuous transmural lesions without gaps, and can be easily manipulated to create all the necessary lesions for a full surgical procedure."

"We are delighted that Dr. Poa, a recognized world-leading authority on surgical ablation, will share his experience with the Cardima Surgical Ablation System at this international gathering of cardiothoracic surgeons and thought-leaders," said Cardima's CEO, Robert Cheney. "Creating awareness about the advanced features of our Surgical Ablation System at key meetings such as the ACTS 2009 and AATS, along with developing Centers for Excellence and broadening distribution are integral parts of our strategy to support product adoption."

Cardima Product Exhibition Information:

-- At the ACTS 2009 meeting, May 6-7, Cardima products and technology will
be displayed at the Exhibit Hall at the Equitable Center. The ACTS 2009
meeting features the latest surgical and interventional therapies for
heart valve and coronary artery diseases, chronic atrial fibrillation
and diseases of the aorta.
-- At AATS, May 9-13, Cardima products will be showcased at the Hynes
Convention Center at exhibition booth #608. The AATS annual meeting
brings together the world's leading scientists in thoracic and
cardiovascular surgery to discuss their latest clinical and research
efforts.

For physicians attending ACTS 2009 or AATS interested in learning more about Cardima's Surgical Ablation Program, please contact Anita Elliot via email at [e-mail].

About Cardima Surgical Ablation System

The Surgical Ablation System uses Cardima's patented technology for the ablation of cardiac tissue. The System incorporates a microcatheter-based surgical probe coupled with Cardima's INTELLITEMP(R), a radiofrequency energy management device. The probe incorporates irrigation, suction and illumination, which aid in placement and lesion depth. The Cardima Surgical Ablation System is able to create deep, long, linear and transmural cardiac lesions without gaps. The small, flexible design offers sole port-hole access, potentially decreasing procedure time, patient hospital stay and discomfort.

About Cardima

Cardima, Inc. has developed the PATHFINDER(R), TRACER(TM) and REVELATION(R) Series of diagnostic catheters, the VUEPORT(R) and NAVIPORT(R) Series of guiding catheters, the INTELLITEMP(R) Energy Management Device and the Surgical Ablation System. All of these Cardima devices have received CE mark approval and U.S. Food and Drug Administration (FDA) 510(k) clearance. The REVELATION(R) Series of ablation catheters with the INTELLITEMP(R) EP Energy Management Device, developed for the treatment of atrial fibrillation (AF), has received CE mark approval and is marketed in Europe.

PATHFINDER(R), TRACER(TM), VUEPORT(R), NAVIPORT(R), REVELATION(R) and INTELLITEMP(R) are registered trademarks of Cardima, Inc.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements are subject to risks and uncertainties. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements as contained in our reports to the Securities and Exchange Commission, including our Forms 10-K and 10-Q. The Company assumes no obligation to update the forward-looking information.




Source: Cardima, Inc.


----------------------------------------------
Company Contact
Cardima
Inc.
Richard Gaston MD
510-354-0300
http://www.Cardima.com
or
Investor Contacts
Lippert/Heilshorn & Associates
Jody Cain or Kevin Mc Cabe
310-691-7100
[e-mail]
[e-mail]

[JefferyDollars]

time to pay attention. hopefully this stock has broken out.

[JefferyDollars]

I think you may be right

[sidedraft]

Somebody is buying up shares, little by little.

[INDY]

Assistant Moderator Position(s) Available!

Experience: able to post messages at warp speed...just joking i type with 4 fingers very slowly

Pay: lol... yeah ok...picture that...ok, a christmas card and maybe a birthday card

Benefits: Respect amongst your peers...lol... yeah ok...picture that...lol ... ok, well i guess sometimes...

Seriously though...if you like the stock and you have 10 minutes a day to help keep the information pipeline clear of distortion and manipulation then you owe it to yourself to participate in a more active role...

thanks in advance

[INDY]

we will be updating the ibox this week thank you for your patience

also... please, if you have any questions that we could add to a couple of surveys, please feel free to share them with me.

thanks to everyone in advance!

[INDY]

This was a proxy statement filed 8/25:

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6121004

[INDY]

Any news on the results of the board meeting 9/8/08?

Annual Meeting of Stockholders to be held at 47266 Benicia Street, Fremont, California, on Monday, September 8, 2008, at 11:00am, local time, and at any and all adjournments of the meeting.

he purpose of the Annual Meeting and the matters to be acted upon are set forth in the following Proxy Statement. As of the date of this Proxy Statement, our Board of Directors knows of no other business, which will be presented for consideration at the Annual Meeting. A stockholder giving a proxy pursuant to this solicitation may revoke it at any time before it is exercised by submitting a duly executed proxy bearing a later date or by delivering to our Secretary a written notice of revocation prior to the Annual Meeting, or by appearing at the meeting and expressing a desire to vote his or her shares in person. Subject to such revocation, all shares represented by a properly executed proxy received prior to or at the Annual Meeting will be voted by the proxy holders whose names are set forth in the accompanying proxy in accordance with the instructions on the proxy. If no instruction is specified with respect to a matter to be acted upon, the shares represented by the proxy will be voted "FOR" the election of the nominees for director and "FOR" each other matter set forth in this Proxy Statement. If any other business properly comes before the meeting, votes will be cast in accordance with the proxies in respect of any such other business in accordance with the judgment of the persons acting under the proxies.

[jscot]

Shares
(Millions)
124.865 Market Cap
(Millions)
199.784

[INDY]

Recent Press Release

FREMONT, CA, Sep 02, 2008 (MARKET WIRE via COMTEX) -- Cardima, Inc. (OTCBB: CADM), a medical device company focused on the treatment of Atrial Fibrillation ("AF") and manufacturer of the Cardima Surgical Ablation System and the REVELATION(R) line of therapeutic electrophysiology catheters, has commenced training physicians in Thailand on the use of the Cardima Surgical Ablation System.
The training on August 22-25, 2008 was performed under the direction of Dr. Li Poa. He worked closely with Dr. Suchart Chaiyaroj, Chief of Cardiothoracic Surgery, and his associate Dr. Khanat Kruthkul, at Ramathibodi Hospital. A total of four patients to date have been successfully ablated using the Cardima Surgical Ablation System.

"The training session here in Thailand went extremely well. The Thai surgeons at Ramathibodi Hospital were extremely supportive of this effort and very impressed with the performance of the Cardima product and its ability to create deep lesions," stated Dr. Poa. "Surgeons from leading Thai medical institutions attended and we are now on our way to establishing a core team of highly proficient surgeons capable of treating atrial fibrillation using the Cardima products."

Dr. Suchart Chaiyaroj commented on behalf of Ramathibodi Hospital and the Thai physicians participating in the program, "This training program and the development of an AF Center of Excellence in Thai medical facilities is a tremendous development for both our domestic health system and our medical tourism program. We very much appreciate the support of Dr. Li Poa, MEDS Global Healthcare, and Cardima in establishing this program. Dr. Khanat Kruthkul, the other physicians who attended and I were very impressed with the Cardima Surgical Ablation System. We look forward to improving the health of many patients once this surgical ablation program is fully launched and we start treating AF patients effectively here in Thailand in large numbers. With the Cardima Surgical System we can now work effectively together with our EP colleagues and offer treatment for stand alone AF."

Several institutions and individuals have provided significant levels of support to this new program to develop Thailand as a Center of Excellence for the treatment of Atrial Fibrillation; in particular, the cardiology faculty at Ramathibodi Hospital, which is associated with Mahidol University, Dr. Li Poa, Dr. Suchart Chaiyaroj, Chief of Cardiothoracic Surgery at Ramathibodi Hospital, Dr. Khanat Kruthkul, the Thai Ministry of Health, MEDS Global Healthcare USA, the Thai Finance Ministry, DKSH Diethelm Ltd., as well as Cardima.

"We need to give a lot of credit to Dr. Li Poa and to the Thai physicians who worked closely to get this training session under way so quickly and to all the companies and institutions that provided support. Cardima has only recently received market approval in Thailand, and to be treating patients and training leading Thai physicians this soon is extremely exciting for everyone at Cardima," said Robert Cheney, CEO of Cardima. "I was very fortunate to be present at Ramathibodi Hospital and to be able to watch Dr. Li Poa and Dr. Suchart Chaiyaroj work together to treat the first Cardima patients here in Thailand. Together with this very successful 'Medical Tourism' program and Thailand's high level of healthcare standards and well developed medical infrastructure, we believe that Cardima has positioned itself to develop a significant market for its products in Thailand in the near future."

Dr. Poa is the Chief of Cardiothoracic Surgery and Cardiac Surgery Program Director at Stamford Hospital, Connecticut, a major teaching affiliate of the Columbia University College of Physicians and Surgeons where he is a faculty member. Dr. Poa specializes in endoscopic cardiac access and the surgical treatment of AF and other minimally invasive techniques.

Dr. Suchart Chaiyaroj is the Chief of Cardiothoracic Surgery at Ramathibodi Hospital which is the teaching hospital for the Faculty of Medicine of Mahidol University, the longest established medical teaching institution in Thailand. Mahidol University and its Faculty of Medicine, where Dr. Suchart Chaiyaroj serves as an Associate Professor of Cardiothoracic Surgery, have been ranked as the leading university and research institution in Thailand.

[INDY]

CADM Chart

[sidedraft]

Bloomberg lists the float as -7.062 million. How does that work?

http://www.bloomberg.com/apps/quote?ticker=CADM:US

[sidedraft]

Form 4 filed:

Lee Victor Shui-Kwai bought about 30k over the last several days. Looking over many Form 4s, this guy has got to be the majority stockholder.

http://www.sec.gov/Archives/edgar/data/1022570/000101376208001458/xslF345/jul72008form4lee_ex.xml

[sidedraft]

30, 2008 08:45 ETCardima, Inc. Receives Chinese State Food and Drug Administration (SFDA) Approval to Market the INTELLITEMP® Energy Management Device in the People's Republic of China
FREMONT, CA--(Marketwire - June 30, 2008) - Cardima, Inc. (OTCBB: CADM) Cardima has been granted a market access license for the INTELLITEMP® by the SFDA and it is the first multichannel radiofrequency (RF) energy delivery device to receive approval for sale in China. The Company was previously awarded an INTELLITEMP patent by the State Intellectual Property Office in 2003.

Existing RF delivery systems currently marketed in China can deliver energy to only one ablation electrode at a time. The INTELLITEMP controls the delivery of RF energy for effective multi-electrode linear ablation in Cardima's systems, namely, the EP Ablation System and the Surgical Ablation System, both designed to treat atrial fibrillation ("AF"). Other Cardima products pending China SFDA approval are the EP ablation catheters and Surgical Ablation Probes.

The INTELLITEMP controls RF energy delivery to any combination of up to 8 electrodes simultaneously along a specially designed Cardima EP catheter or surgical probe. In comparison to standard "drag and burn" ablation technologies, employing the INTELLITEMP in combination with a Cardima linear ablation catheter or surgical probe produces lesions that have penetrating depth, without gaps along a linear trajectory. These are key elements in delivering effective clinical results.

Cardima's CEO, Robert Cheney, commented: "We are delighted to have received approval from the SFDA. This is a significant milestone for Cardima. China is one of Cardima's primary target markets with a large aging population that can benefit from the effective treatment of AF using a multi-electrode linear ablation system, like Cardima's. We are well positioned to enter the China market having already taken the initiative to establish relationships with leading physicians and institutions involved in the treatment of AF."

A 2004 study from Peking University estimates that AF currently affects approximately 10 million patients in China. Published scientific literature in China shows that the percentage of hospital admissions for AF has increased at a faster rate than for cardiovascular admissions generally. As in other countries, the distribution of AF events in China progressively increases with age. China's population of people over the age of 50 will be 332 million in 2010 and will increase to 525 million by 2025, according to the International Institute for Applied Systems Analysis. Studies also show that the incidence of stroke among AF cases is high in China, yet it is difficult to enforce a drug regimen for preventing stroke in this patient population. Therefore, it will be a significant challenge for the public healthcare system in China to manage, control and treat the growing numbers of AF patients. China is one of the world's fastest growing medical markets and holds a high regard for medical products manufactured in the United States and Europe.

The INTELLITEMP is marketed in the U.S.A. as part of the Cardima Surgical Ablation System. It is CE Marked in the EU as a component of both the Cardima Surgical and EP Ablation Systems.

About Cardima

Cardima, Inc. has developed the PATHFINDER®, TRACER® and VUEPORT® Series of diagnostic catheters, the NAVIPORT® Series of guiding catheters, the REVELATION® Series of ablation catheters, the Surgical Ablation System with its series of ablation probes, and the INTELLITEMP® Energy Management Device Series for RF (radiofrequency) energy management. These devices are CE marked and/or received United States FDA 510(k) clearance. The REVELATION Series of ablation catheters with the INTELLITEMP EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) with CE mark approval in Europe; it is not yet commercially approved in the United States.

For more information, please visit the Company's website at www.cardima.com.

The PATHFINDER®, TRACER®, VUEPORT®, NAVIPORT®, REVELATION® and INTELLITEMP® are registered trademarks of Cardima, Inc.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements, including but not limited to the employment of Cardima's INTELLITEMP in combination with a Cardima linear ablation catheter or surgical probe produces lesions that have penetrating depth, without gaps along a linear trajectory. Potential risks and uncertainties include, but are not limited to: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure FDA approval for the EP ablation applications in the USA and CE mark for the Surgical Ablation probe series with Sheath. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, the Company's Quarterly Report on Form 10-QSB and in the Company's other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:

Dr. Richard Gaston
Cardima, Inc.
[phone]
http://www.Cardima.com

[sidedraft]

So, $2.35 printed today, currently $2.18, B/A $2.18/$2.20.

Up about 100% in the last two weeks, not too shabby!

[sharp knife]

Don't stop now! Its up up and away, maybe soon its back on the big exchange. England first next Hawaii soon everywhere I hope.

[sidedraft]

There is a reason for this, I wish I knew what it is.

[sidedraft]

Better and better, day by day.

  Date        Time       Price  Ask    Bid   Volume 
  
 05/30/08	10:19:24	1.20	1.18	1.20	4467

[sidedraft]

Anybody want to venture a guess as to why the PPS is climbing, climbing, climbing?

No complaints, mind you, just can't find a reason.

[sidedraft]

Nice chart!

[sidedraft]

Up about 22% in the past 5 days, nice steady climb, somebodies are sneaking some shares in advance of...............?

[sidedraft]

The E is going away on next Tuesday, the 4th.

08/31/2007 13:50:03|S1|CADM|CADME|Cardima, Inc. NEW Common Stock|Cardima, Inc. NEW Common Stock|09/04/2007|**|||U

[sidedraft]

Now this from today's daily list, tough to get ahead here. The dreaded "E".

08/21/2007 13:42:42|S1|CADME|CADM|Cardima, Inc. NEW Common Stock|Cardima, Inc. NEW Common Stock|08/23/2007|Delinquent **|||U

[sidedraft]

Snuck up on me!

CARDIMA ANNOUNCES ONE-FOR-TEN REVERSE STOCK SPLIT
FREMONT, CA. (July 31, 2007) – Cardima, Inc. (OTCBB: CADM.OB, formerly OTCBB: CRDM.OB), developer of the REVELATION® Tx, REVELATION® T-Flex ablation microcatheters and INTELLITEMP® Energy Management Device, announces today that its Board of Directors has declared a reverse stock split, at a 1 for 10 ratio, effective at the opening of trading on July 31, 2007. Following the split, the Company’s Common Stock will trade under a new ticker symbol, “CADM”. The Board declared this reverse stock split pursuant to the discretionary authority granted by the vote of a majority of the Company’s outstanding shares at the 2007 Annual Shareholders Meeting held June 28, 2007.
Registered stockholders will receive a letter, to be mailed this week, explaining the steps and including the forms required to obtain a new stock certificate evidencing their post-split shares. No fractional shares will be issued in connection with the reverse stock split. Those stockholders, who would otherwise be entitled to receive fractional shares, because they hold a number of shares not divisible by 10, will be entitled upon surrender of their certificates representing such shares, to a cash payment in lieu thereof. Stockholders with shares in brokerage accounts will be contacted by their brokers with instructions. American Stock Transfer and Trust Company will act as the exchange agent, and can be contacted at [phone].

About Cardima
Cardima, Inc. has developed the PATHFINDER® series of diagnostic catheters, the REVELATION® series ablation system and the Surgical Ablation System for the diagnosis and treatment of tachycardias. The REVELATION® series with the INTELLITEMP energy management system was developed for the treatment of atrial fibrillation (AF) originating in the pulmonary veins of the heart and received CE mark approval in Europe. The Surgical Ablation System (SAS) with an INTELLITEMP received a 510(K) approval in the U.S. by the FDA. The PATHFINDER and the REVELATION family of devices are intended for in use of in the Electro-physiology (EP) market and our Surgical Ablation System (SAS) for use in the surgical market. For more information please visit the Company's website at http://www.cardima.com.

Forward Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risks associated with the Apix loan facility's restrictive covenants, security interest, fee provisions and other terms and conditions; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the first quarter ended March 31, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:

Cardima, Inc.
Gabriel B. Vegh
510-354-0300
http://www.cardima.com/

Source: Cardima, Inc.

[Three_Kings]

Nice...

Flip...

TK

[Three_Kings]

Started to sample some...

In the low .04s today...

TK

[MBT]

Seemed like this is a DEAD board ! Is everyone jumping ship ?

[MBT]

Could one of you give me some thought about this stock ? Not looking forward to make quick bucks but rather to stay LONG if there is a future in this. TIA.

[TexasRedGT]

already filled one gap...

will it fill them both?

[GotOptions?]

I am hoping for a recovery back to the .15 to .20 area. Time will tell.

[Railrunner]

just the start of a huge run!

[Three_Kings]

Looking good today...

TK

[illhonky]

STRONG support at .04

[illhonky]

I loaded up on monday, but there's no volume.

[JusDePomme]

Add lots yesterday! Way oversold! Super cheap! Expect huge upside from here

[illhonky]

I think th MM is still sleeping.

[illhonky]

Bottomed at .04???

[ganman]

Well this was < .05 before the Microcatheter project was announced...so......

[rbl100]

We will see???